Solara Active Pharma Sciences Limited

Total Valuation

Solara Active Pharma Sciences Limited carries a market capitalization of 27.00B, placing it among publicly traded companies globally. Its enterprise value stands at 24.70B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Solara Active Pharma Sciences Limited currently has 48.17M shares outstanding.

Valuation Ratios

Solara Active Pharma Sciences Limited trades at a trailing price-to-earnings ratio of 523.97. The price-to-sales ratio is 1.34, and the price-to-book ratio stands at 41.35.

Enterprise Valuation

On an enterprise value basis, Solara Active Pharma Sciences Limited trades at an EV/EBITDA multiple of 28.37 and an EV/FCF ratio of 26.07. The EV/Sales ratio of 1.80 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 28.37 provides insight into valuation relative to core operating earnings.

Financial Position

Solara Active Pharma Sciences Limited maintains a current ratio of 0.96, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.68, indicating elevated leverage, while an interest coverage ratio of 0.92 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Stock Price Statistics

Solara Active Pharma Sciences Limited's stock has declined approximately -11.50988% over the past 52 weeks. The 50-day moving average sits at 548.46, while the 200-day moving average is 533.85.

Income Statement

Over the trailing twelve months, Solara Active Pharma Sciences Limited generated 13.69B in revenue and converted that into -74.10M in net income, yielding earnings per share of -1.71. EBITDA reached 870.70M, while operating income came in at 870.70M.

Balance Sheet

Solara Active Pharma Sciences Limited holds 598.80M in cash and equivalents against 6.87B in total debt, resulting in a net debt position of 6.60B. Total book value stands at 445.10M, with working capital of -358.10M providing operational flexibility.

Margins

Solara Active Pharma Sciences Limited operates with a gross margin of 50.00, reflecting its pricing power and cost economics. The operating margin of 6.36 and net profit margin of -0.54 provide insight into operational efficiency.

Stock Splits

Solara Active Pharma Sciences Limited's most recent stock split took place on May 15, 2024 with a 200:217 split ratio.

Scores

Solara Active Pharma Sciences Limited posts an Altman Z-Score of 1.85, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.